Filgrastim ELISA Kit for Reliable Quantification

Introductions

Commercially available kits utilize highly specific monoclonal antibodies to distinguish filgrastim from endogenous G-CSF and other hematopoietic growth factors. This specificity is paramount given the structural similarity between therapeutic rhG-CSF and naturally occurring G-CSF, which shares 175 amino acids with filgrastim but lacks the N-terminal methionine residue. Modern kits achieve this discrimination through epitope-specific antibody design, ensuring minimal cross-reactivity (<0.1%) with related cytokines like GM-CSF or M-CSF.

Technology Platform

Sample Type

Serum/Plasma
Cell Culture Supernatant
Formulation Samples

Key Processing

Collect in heparin/EDTA tubes
Centrifuge at 3000×g for 10min
Store ≤5 days at 2-8°C
Harvest from CHO cell cultures
Filter through 0.22μm membrane
Dilute 1:100 in assay buffer
Dilute drug product 1:1000 with dilution buffer
Avoid freeze-thaw cycles

Detection Metrics

LOD: 0.1 ng/mL
CV<7% (intra-assay)
Linear range: 0.3-50 ng/mL
Recovery rate: 95-105%
LOD: 0.05 ng/mL
Inter-assay CV<10%
Accuracy: ±5% of target concentration
Precision: CV<6%

Main Uses

Therapeutic drug monitoring
Pharmacokinetic studies
Biopharmaceutical QC
Production process monitoring
Final product release
Stability testing

Key Components for Reliable Quantification

High Specificity And Affinity Antibodies

The capture antibody and detection antibody used in the reagent kit are the core of its performance. The ideal antibody corresponds to the following characteristics:
High specificity: They should only specifically bind to Filgrastim and not cross react with endogenous G-CSF or other similar molecules in the sample.
High affinity: The strong binding affinity ensures efficient capture of Filgrastim even at low concentrations, thereby improving the sensitivity of the assay.
Different epitope recognition: Capture antibodies and detection antibodies should recognize different epitopes on the Filgrastim molecule to ensure that the Filgrastim molecule is completely "sandwiched" between the two, avoiding detection failure caused by antigen degradation or conformational changes.

Traceable High-Purity Filgrastim Standard

Standard samples are benchmarks used to construct standard curves, and their quality directly determines the accuracy of quantitative results. A high-quality Filgrastim ELISA kit must include:
High purity: The standard should be high-purity recombinant Filgrastim, whose concentration has been precisely calibrated.
Traceability: Ideally, its concentration should be traceable to internationally recognized standards. This ensures comparability of results between different laboratories and batches of reagent kits.
Stability: The standard should remain stable within the validity period of the reagent kit to prevent degradation.

Optimized Matrix Diluent And Buffer Solution

Biological samples, especially serum and plasma, contain complex proteins and potential interfering substances. Matrix effects may lead to distorted measurement results. An excellent reagent kit will provide optimized diluent for diluting standards and samples to:
Minimize matrix effects: Ensure that the standard and diluted samples are in similar chemical environments, so that the standard curve can accurately reflect the concentration in the sample.
Maintaining pH and ionic strength: providing the optimal environment for antibody antigen reactions.
Inhibit non-specific binding: reduce background noise and improve signal-to-noise ratio.

Filgrastim Elisa Kits

Parameter	Details
Product name	Human Anti-Filgrastim ELISA Kit
Intended Use	For the qualitative determination of antibodies to filgrastim in human serum or plasma.
Storage	Store kit components at 2-8°C unless specified otherwise. DO NOT USE past kit expiration date. Some vials contain a small amount of reagents. Spin tubes on pulse setting prior to opening.
Contents of Kit	Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes. It is produced by recombinant DNA technology. It serves to stimulate the production of granulocytes. Granulocyte-colony stimulating factor (G-CSF) is a growth factor and an essential cytokine belonging to the CSF family of hormone hematopoietic cell proliferation and differentiation. Filgrastim is used to treat neutropenia, stimulating the bone marrow to increase production of neutrophils. The causes of neutropenia include chemotherapy and bone marrow transplantation.

Applications and Scientific Relevance

Filgrastim ELISA systems support diverse research and clinical applications:

Pharmacokinetic Studies

Enable characterization of filgrastim's time-concentration profiles after subcutaneous (SC) or intravenous (IV) administration, with typical Tmax of 4–6 hours for SC dosing and elimination half-life of 3.5–5 hours. Researchers use these data to optimize dosing intervals in oncology protocols.

Biosimilar Development

Critical for demonstrating bioequivalence between reference filgrastim and biosimilars through comparative potency and stability testing. Regulatory guidelines require ELISA-based quantification to support pharmacokinetic similarity.

Therapeutic Drug Monitoring

In bone marrow transplant settings, serial measurements guide dose adjustments to maintain neutrophil counts above 1.0×10^9/L, reducing infection risk without excessive myeloproliferation.

The Role of ELISA in Filgrastim Quantification

The accurate quantification of Filgrastim is essential for monitoring therapeutic response, adjusting dosing regimens, and ensuring patient safety. ELISA, a widely used immunoassay technique, is particularly suitable for the detection and quantification of proteins such as Filgrastim. The ELISA method relies on the specific binding of the target protein to an antibody-coated surface, followed by detection using enzyme-labeled antibodies and a colorimetric or fluorometric readout .
The use of ELISA for Filgrastim quantification offers several advantages, including high sensitivity, specificity, and reproducibility. These characteristics make ELISA an ideal tool for both clinical diagnostics and research applications. The development of standardized ELISA kits for Filgrastim has facilitated the widespread adoption of this method in clinical laboratories and research institutions.

Advantages of Filgrastim ELISA Kit

Specificity

The sandwich ELISA design minimizes cross-reactivity with other cytokines (e.g., G-CSF) or matrix components. This specificity is vital for distinguishing filgrastim ADA from background immunoglobulins.

Broad Dynamic Range

Kits cover a wide detection range, accommodating both low and high concentrations. This eliminates the need for multiple dilutions, streamlining workflows in pharmacokinetic (PK) studies and pharmaceutical quality control.

Cost Effectiveness

ELISA kits are less expensive than RT-PCR, especially for high-throughput detection. It requires minimal equipment (microplate readers) and can be performed by trained technicians.

Conclusion

Filgrastim ELISA is a powerful and validated quantitative tool. It has become the cornerstone of biopharmaceuticals and clinical research due to its outstanding specificity, sensitivity, and reliability. However, relying solely on reagent kits is not enough. Only by strictly adhering to standard operating procedures, conducting comprehensive method validation, and implementing strict quality control can researchers ensure the accuracy and reliability of the data obtained. The precise quantification of Filgrastim blood drug concentration not only promotes the development and market launch of new drugs, but also provides key basis for clinical doctors to develop personalized treatment plans, ultimately benefiting patients.

Inquiry Basket

Loading ......

Inquiry